vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and Magyar Bancorp, Inc. (MGYR). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $8.9M, roughly 1.6× Magyar Bancorp, Inc.). Magyar Bancorp, Inc. runs the higher net margin — 35.4% vs -34.7%, a 70.1% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 19.0%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Magyar Bank is a bank based in New Brunswick, New Jersey with branches in Central Jersey.
FENC vs MGYR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $8.9M |
| Net Profit | $-4.8M | $3.1M |
| Gross Margin | — | — |
| Operating Margin | -18.5% | 48.3% |
| Net Margin | -34.7% | 35.4% |
| Revenue YoY | 73.8% | 19.0% |
| Net Profit YoY | -141.1% | 50.4% |
| EPS (diluted) | $-0.17 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $8.9M | ||
| Q3 25 | $12.5M | — | ||
| Q2 25 | $9.7M | — | ||
| Q1 25 | $8.8M | — | ||
| Q4 24 | $7.9M | — | ||
| Q3 24 | $7.0M | — | ||
| Q2 24 | $7.3M | $7.2M | ||
| Q1 24 | $25.4M | $7.5M |
| Q4 25 | $-4.8M | $3.1M | ||
| Q3 25 | $-638.0K | — | ||
| Q2 25 | $-3.2M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-5.7M | — | ||
| Q2 24 | $-5.6M | $1.7M | ||
| Q1 24 | $12.8M | $1.9M |
| Q4 25 | -18.5% | 48.3% | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -28.3% | — | ||
| Q1 25 | -9.2% | — | ||
| Q4 24 | -11.8% | — | ||
| Q3 24 | -74.6% | — | ||
| Q2 24 | -69.4% | 30.5% | ||
| Q1 24 | 54.2% | 32.1% |
| Q4 25 | -34.7% | 35.4% | ||
| Q3 25 | -5.1% | — | ||
| Q2 25 | -32.7% | — | ||
| Q1 25 | -13.3% | — | ||
| Q4 24 | -25.0% | — | ||
| Q3 24 | -82.2% | — | ||
| Q2 24 | -76.5% | 23.5% | ||
| Q1 24 | 50.6% | 25.1% |
| Q4 25 | $-0.17 | $0.50 | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.20 | $0.27 | ||
| Q1 24 | $0.41 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $34.1M |
| Total DebtLower is stronger | — | $49.1M |
| Stockholders' EquityBook value | $35.5M | $121.7M |
| Total Assets | $70.6M | $1.0B |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | $34.1M | ||
| Q3 25 | $21.9M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $22.7M | — | ||
| Q4 24 | $26.6M | — | ||
| Q3 24 | $40.3M | — | ||
| Q2 24 | $43.1M | $49.0M | ||
| Q1 24 | $51.2M | $50.0M |
| Q4 25 | — | $49.1M | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
| Q4 25 | $35.5M | $121.7M | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $-7.5M | — | ||
| Q1 25 | $-5.9M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-5.2M | — | ||
| Q2 24 | $-1.4M | $109.0M | ||
| Q1 24 | $3.0M | $107.6M |
| Q4 25 | $70.6M | $1.0B | ||
| Q3 25 | $49.3M | — | ||
| Q2 25 | $44.9M | — | ||
| Q1 25 | $46.4M | — | ||
| Q4 24 | $44.9M | — | ||
| Q3 24 | $58.9M | — | ||
| Q2 24 | $63.2M | $944.4M | ||
| Q1 24 | $69.2M | $928.6M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $3.7M |
| Free Cash FlowOCF − Capex | — | $3.7M |
| FCF MarginFCF / Revenue | — | 41.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | $8.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $3.7M | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $-3.7M | — | ||
| Q1 25 | $-4.3M | — | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $-2.2M | — | ||
| Q2 24 | $-8.4M | $1.7M | ||
| Q1 24 | $39.0M | $553.0K |
| Q4 25 | — | $3.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.5M | ||
| Q1 24 | — | $428.0K |
| Q4 25 | — | 41.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 21.5% | ||
| Q1 24 | — | 5.7% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | 1.17× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | 3.04× | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
